<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db04630 DrugCentral: aldosterone Synonymous :(&#43;)-aldosterone | (11β)-11,21-dihydroxy-3,20-dioxopregn-4-en-18-al | 11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al | 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al | aldosterona | aldosterone | aldosteronum 
Drug Sentece Context Table 1. Analysis of context sentence of aldosterone gene in 25 abstracts.">

  
  <link rel="alternate" hreflang="en-us" href="https://bio-hub.github.io/platcovid/drugpanel/aldosterone/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/platcovid/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/platcovid/index.webmanifest">
  <link rel="icon" type="image/png" href="/platcovid/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/platcovid/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://bio-hub.github.io/platcovid/drugpanel/aldosterone/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://bio-hub.github.io/platcovid/drugpanel/aldosterone/info/">
  <meta property="og:title" content="ALDOSTERONE | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db04630 DrugCentral: aldosterone Synonymous :(&#43;)-aldosterone | (11β)-11,21-dihydroxy-3,20-dioxopregn-4-en-18-al | 11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al | 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al | aldosterona | aldosterone | aldosteronum 
Drug Sentece Context Table 1. Analysis of context sentence of aldosterone gene in 25 abstracts."><meta property="og:image" content="https://bio-hub.github.io/platcovid/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://bio-hub.github.io/platcovid/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>ALDOSTERONE | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/platcovid/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/platcovid/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/platcovid/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/platcovid/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/platcovid/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/platcovid/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/platcovid/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/platcovid/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">ALDOSTERONE</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db04630' target='_blank'>db04630</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=aldosterone" target="_blank">aldosterone</a> <br>
Synonymous :(+)-aldosterone | (11β)-11,21-dihydroxy-3,20-dioxopregn-4-en-18-al | 11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al | 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al | aldosterona | aldosterone | aldosteronum
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>aldosterone</em> gene in 25 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/32228252" target="_blank">32228252</a>
</td>
<td style="text-align:center;">
ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades ANG II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7), which antagonizes the effects of ANG II.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32301766" target="_blank">32301766</a>
</td>
<td style="text-align:center;">
Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. […] We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32314329" target="_blank">32314329</a>
</td>
<td style="text-align:center;">
ACE2 counteracts ACE and angiotensin II in the renin-angiotensin-aldosterone system (RAAS) and has critical functions in the lung and cardiovascular system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32324352" target="_blank">32324352</a>
</td>
<td style="text-align:center;">
Inhibitors of the renin-angiotensin aldosterone system should be continued when there is a solid indication, and stopped in case of hemodynamic problems.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32341103" target="_blank">32341103</a>
</td>
<td style="text-align:center;">
The renin-angiotensin-aldosterone system (RAAS) is crucial to the homeostasis of both the cardiovascular and respiratory systems. […] Importantly, SARS-CoV-2 utilises and interrupts this pathway directly, which could be described as the renin-angiotensin-aldosterone-SARS-CoV-2-axis (RAAS-SCoV-axis).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32348783" target="_blank">32348783</a>
</td>
<td style="text-align:center;">
Early clinical evidence suggests that severe cases of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are frequently characterized by hyperinflammation, imbalance of renin-angiotensin-aldosterone system, and a particular form of vasculopathy, thrombotic microangiopathy, and intravascular coagulopathy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32352535" target="_blank">32352535</a>
</td>
<td style="text-align:center;">
Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32354022" target="_blank">32354022</a>
</td>
<td style="text-align:center;">
ACE2 plays an essential role in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32354800" target="_blank">32354800</a>
</td>
<td style="text-align:center;">
Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32356628" target="_blank">32356628</a>
</td>
<td style="text-align:center;">
There is concern about the potential of an increased risk related to medications that act on the renin-angiotensin-aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32360703" target="_blank">32360703</a>
</td>
<td style="text-align:center;">
Physiologically, ACE2 degrades angiotensin II, the master regulator of the renin-angiotensin-aldosterone system (RAAS), thereby converting it into vasodilatory molecules, which have well-documented cardio-protective effects.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32366740" target="_blank">32366740</a>
</td>
<td style="text-align:center;">
A concern was raised regarding the safety of ibuprofen use because of its role in increasing ACE2 levels within the Renin-Angiotensin-Aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32367746" target="_blank">32367746</a>
</td>
<td style="text-align:center;">
Coronavirus binding to angiotensin-converting enzyme 2, a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. […] We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the angiotensin-converting enzyme 2/angiotensin-(1-7) pathway in children and the clinical evidence for how angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers affect this important pathway.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32376099" target="_blank">32376099</a>
</td>
<td style="text-align:center;">
In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32383624" target="_blank">32383624</a>
</td>
<td style="text-align:center;">
This might be due to the fact that ACE2 is the receptor for the virus to enter human cells, but, on the contrary, that ACE2 expression is downregulated following SARS-1 infection, resulting in disproportionate activation of renin-angiotensin-aldosterone system and exacerbated pneumonia progression.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32387238" target="_blank">32387238</a>
</td>
<td style="text-align:center;">
SARS-CoV-2 has a major impact on the Renin Angiotensin Aldosterone System (RAAS), through its binding to the membrane cellular glycoprotein, Angiotensin Converting Enzyme-2 (ACE-2), then infecting cells for replication.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32388331" target="_blank">32388331</a>
</td>
<td style="text-align:center;">
Compromised innate immunity, pro-inflammatory cytokine milieu, reduced expression of ACE2 and use of renin-angiotensin-aldosterone system antagonists in people with diabetes mellitus contribute to poor prognosis in COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32388565" target="_blank">32388565</a>
</td>
<td style="text-align:center;">
Recent reports suggest an association with use of renin-angiotensin-aldosterone system (RAAS) inhibitors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32391169" target="_blank">32391169</a>
</td>
<td style="text-align:center;">
During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. […] Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32394850" target="_blank">32394850</a>
</td>
<td style="text-align:center;">
The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients’ age and comorbidities.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32401442" target="_blank">32401442</a>
</td>
<td style="text-align:center;">
ACE2 is not only an enzyme that counters the effects of the renin-angiotensin-aldosterone system (RAAS) but is also the entry receptor for SARS-CoV-2, the virus of the Covid-19 pandemic.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405229" target="_blank">32405229</a>
</td>
<td style="text-align:center;">
Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32412156" target="_blank">32412156</a>
</td>
<td style="text-align:center;">
A key role may be that of the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32412303" target="_blank">32412303</a>
</td>
<td style="text-align:center;">
Like other coronaviruses, SARS-CoV-2 recognizes the human Angiotensin Converting Enzyme 2 (hACE2) as a cellular receptor that allows it to infect different host cells, and likely disrupts the renin-angiotensin-aldosterone system (RAAS) homeostasis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32413342" target="_blank">32413342</a>
</td>
<td style="text-align:center;">
There are currently no recommendations in favour of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32414646" target="_blank">32414646</a>
</td>
<td style="text-align:center;">
This molecule is a peptidase expressed at the surface of lung epithelial cells and other tissues, that regulates the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32416785" target="_blank">32416785</a>
</td>
<td style="text-align:center;">
Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32418199" target="_blank">32418199</a>
</td>
<td style="text-align:center;">
In human physiology, ACE2 is a pivotal counter-regulatory enzyme to ACE by the breakdown of angiotensin II, the central player in the renin-angiotensin-aldosterone system (RAAS) and the main substrate of ACE2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32418532" target="_blank">32418532</a>
</td>
<td style="text-align:center;">
SARS-CoV-2 / COVID-19 and the ‘Renin-Angiotensin’ System The ubiquitous ‘Renin-Angiotensin’ system (RAS), also referred to as ‘Renin-Angiotensin-Aldosterone’ system, plays a crucial physiological role in humans as being a key regulator of renal, cardiovascular and innate immune functions [1, 2].
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32420884" target="_blank">32420884</a>
</td>
<td style="text-align:center;">
Despite the rapid evolution of data on this pandemic, this review aims to highlight the cardiovascular considerations related to COVID-19 whether as comorbidities including concerns and uncertainty regarding the effect of renin-angiotensin-aldosterone system (RAAS) inhibitors on angiotensin conversion enzyme 2 or related to acute cardiovascular complications.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32421367" target="_blank">32421367</a>
</td>
<td style="text-align:center;">
The main host receptor of the SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2), a major component of the renin-angiotensin-aldosterone system (RAAS).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32432519" target="_blank">32432519</a>
</td>
<td style="text-align:center;">
We discuss the possible excess risk for COVID-19 infection in the context of the common conditions among shiftworkers, including nurses, doctors, and first responders, among others of high exposure to the contagion, of sleep imbalance and circadian disruption.<b>Abbreviations:</b> ACE2: Angiotensin-converting enzyme 2; APC: Antigen﻿-presenting ﻿cells; CCL: Chemokine (C-C motif) ligand; CD<sup>+</sup>: ﻿Adhesion molecule expression; COVID-19: 2019 coronavirus disease; DCs: Dendritic cells; GH: Growth hormone; HPA: Hypothalamic-pituitary-adrenal; HSF: Heat shock factor; HSP70: Heat shock protein 70; HSP90: Heat shock protein 90; IL: Interleukin; INFγ: Interferon-gamma; LT/LB: T/B lymphocytes; MHC: Major histocompatibility complex; NK: Natural ﻿killer; RAAS: renin-angiotensin-aldosterone system; SARS: ﻿Severe acute respiratory syndrome; SCN: Suprachiasmatic nucleus;SD: Sleep deprivation; SNS: Sympathetic nervous system; Th1/Th2: T helper lymphocytes 1/2; TLR2/TLR4: Toll-like receptor 2/4; TNF-α: Tumor ﻿necrosis ﻿factor alpha; VEGF: Vascular endothelial growth factor.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32435607" target="_blank">32435607</a>
</td>
<td style="text-align:center;">
As a crucial enzyme of renin-angiotensin-aldosterone system (RAAS), ACE2 not only mediates the virus entry but also affects the pathophysiological process of virus-induced acute lung injury (ALI), as well as other organs’ damage.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32442285" target="_blank">32442285</a>
</td>
<td style="text-align:center;">
Renin-angiotensin-aldosterone system (RAAS) inhibitors may facilitate host cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or attenuate organ injury via RAAS blockade.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446267" target="_blank">32446267</a>
</td>
<td style="text-align:center;">
Kidney transplant recipients are commonly prescribed renin-angiotensin-aldosterone system (AAS) inhibitors given the prevalence of hypertension, diabetes, and cardiovascular disease. […] As the angiotensin-converting enzyme 2 (ACE2) facilitates the entry of coronaviruses into target cells, there have been hypotheses that preexisting use of Renin-Angiotensin-Aldosterone System (RAAS) inhibitors may increase the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32452762" target="_blank">32452762</a>
</td>
<td style="text-align:center;">
Genetic alteration of ENaC-α causes aldosterone dysregulation in patients, highlighting that the FURIN site is critical for activation of ENaC.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32458694" target="_blank">32458694</a>
</td>
<td style="text-align:center;">
The continued use of angiotensin converting enzyme inhibitor (ACEIs) and angiotensin II receptor blockers (ARBs) which are part of renin-angiotensin-aldosterone system (RAAS) inhibitors in COVID-19 patients with hypertension has become controversial.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32461198" target="_blank">32461198</a>
</td>
<td style="text-align:center;">
Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32470515" target="_blank">32470515</a>
</td>
<td style="text-align:center;">
The coronavirus disease 2019 (COVID-19) is caused by SARS-CoV2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2 (ACE-2).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32472191" target="_blank">32472191</a>
</td>
<td style="text-align:center;">
In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA<sub>1c</sub>, diabetic complications or glucose-lowering therapies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32496364" target="_blank">32496364</a>
</td>
<td style="text-align:center;">
When the coronavirus disease 2019 (COVID-19) wreaked an unprecedented havoc of an escalating number of deaths and hospitalization in the United States, clinicians were faced with a myriad of unanswered questions, one of the them being the implication of the renin-angiotensin-aldosterone system in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32498076" target="_blank">32498076</a>
</td>
<td style="text-align:center;">
The mortality rates were similar between the renin-angiotensin-aldosterone system (RAAS) inhibitor (4/183) and non-RAAS inhibitor (19/527) cohorts (2.2% vs.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32501190" target="_blank">32501190</a>
</td>
<td style="text-align:center;">
Demographic and clinical comorbidities associated with the severity of infection suggest that possible variants known to influence the renin-angiotensin-aldosterone system pathway (particularly those that influence ACE2) may contribute to the heterogenous infection response. […] Hypertension medication modulation, may alter ACE2 and angiotensin(1-7), particularly in variants that have been shown to influence renin-angiotensin-aldosterone system function, which could be clinically useful in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32511678" target="_blank">32511678</a>
</td>
<td style="text-align:center;">
The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32523145" target="_blank">32523145</a>
</td>
<td style="text-align:center;">
The drugs that act on the renin-angiotensin-aldosterone system are in many cases the backbone for the management of these diseases, it has been known for a long time that these drugs significantly increase the expression of receptors for angiotensin conversion enzyme type 2 in the lung tissue.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32527699" target="_blank">32527699</a>
</td>
<td style="text-align:center;">
Debate has been generated as to the association between antihypertensive therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and SARS-CoV-2 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32544563" target="_blank">32544563</a>
</td>
<td style="text-align:center;">
The virus-mediated down-regulation of ACE2 causes a burst of inflammatory cytokine release through dysregulation of the renin-angiotensin-aldosterone system (ACE/angiotensin II/AT1R axis), attenuation of Mas receptor (ACE2/MasR axis), increased activation of [des-Arg9]-bradykinin (ACE2/bradykinin B1R/DABK axis), and activation of the complement system including C5a and C5b-9 components.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32550040" target="_blank">32550040</a>
</td>
<td style="text-align:center;">
On the other hand, ACE2 negatively regulates the renin-angiotensin-aldosterone system (RAAS) primarily by converting angiotensin II to angiotensin 1-7, which exerts a beneficial effect on coronavirus-induced acute lung injury.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32558211" target="_blank">32558211</a>
</td>
<td style="text-align:center;">
We explore potential interactions between anti-diabetic medications and renin-angiotensin-aldosterone-system inhibitors with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32565254" target="_blank">32565254</a>
</td>
<td style="text-align:center;">
SARS-CoV2 has been suggested to modulate the renin-angiotensin-aldosterone system (RAAS).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32567171" target="_blank">32567171</a>
</td>
<td style="text-align:center;">
Obesity is usually associated with dysregulated renin-angiotensin-aldosterone (RAAS) axis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32574273" target="_blank">32574273</a>
</td>
<td style="text-align:center;">
ACE2 is part of the wider renin-angiotensin-aldosterone system (RAAS) and is upregulated via compounds, which inhibits the classical ACE, thereby plasma aldosterone and aldosterone receptor (MR) activation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32581799" target="_blank">32581799</a>
</td>
<td style="text-align:center;">
We examine the crosstalk between the renin-angiotensin-aldosterone system and mitogen activated kinase pathways that potentially links cardiovascular predisposition and/or outcome to SARS-CoV-2 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32582574" target="_blank">32582574</a>
</td>
<td style="text-align:center;">
In this perspective, we predominantly focus on the impact of SARS-CoV-2 infection on ACE2 and dysregulation of the protective effect of ACE2/MAS/G protein pathway vs. the deleterious effect of Renin/Angiotensin/Aldosterone. […] We discuss the potential effect of invasion of SARS-CoV-2 on the function of ACE2 and the loss of the protective effect of the ACE2/MAS pathway in alveolar epithelial cells and how this may amplify systemic deleterious effect of renin-angiotensin aldosterone system (RAS) in the host.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32589258" target="_blank">32589258</a>
</td>
<td style="text-align:center;">
Use of renin-angiotensin-aldosterone system inhibitors was not associated with mortality after adjusting by baseline risk factors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32624690" target="_blank">32624690</a>
</td>
<td style="text-align:center;">
Despite angiotensin-converting enzyme 2 serving as the portal for infection, the continuation of clinically indicated renin-angiotensin-aldosterone blockers is recommended according to the present evidence.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32627330" target="_blank">32627330</a>
</td>
<td style="text-align:center;">
Some investigations speculated about the association between renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and increased mortality in these patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32628137" target="_blank">32628137</a>
</td>
<td style="text-align:center;">
Renin-angiotensin-aldosterone-system (RAAS) inhibitors may increase the expression of angiotensin-converting enzyme 2, which is the receptor for SARSCoV-2 Spike protein.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32653530" target="_blank">32653530</a>
</td>
<td style="text-align:center;">
In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin-angiotensin-aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32654082" target="_blank">32654082</a>
</td>
<td style="text-align:center;">
Endothelial dysfunction, activation of the renin-angiotensin-aldosterone system (RAAS) with the release of procoagulant plasminogen activator inhibitor (PAI-1), and hyperimmune response with activated platelets seem to be significant contributors to thrombogenesis in COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32654555" target="_blank">32654555</a>
</td>
<td style="text-align:center;">
This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32654557" target="_blank">32654557</a>
</td>
<td style="text-align:center;">
There have been concerns on whether alterations of ACE2 expression by renin-angiotensin-aldosterone system (RAAS) inhibitors would contribute to the infectivity and severity of coronavirus disease 2019 (COVID-19).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32658389" target="_blank">32658389</a>
</td>
<td style="text-align:center;">
In the present review, we highlight possible pathways involved in the pathogenesis of COVID-19 and potential therapeutic targets, focusing on the role of the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32662949" target="_blank">32662949</a>
</td>
<td style="text-align:center;">
On the basis of the link between inflammation, fibrosis, aldosterone, and extracellular matrix regulation, we aimed to investigate the effect of an early intervention with the mineralocorticoid receptor antagonist (MRA) eplerenone on cardiac remodelling in a murine model of persistent coxsackievirus B3 (CVB3)-induced myocarditis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32691370" target="_blank">32691370</a>
</td>
<td style="text-align:center;">
Angiotensin-converting enzyme 2 (ACE2) plays an important role as a member of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II (Ang II) into angiotensin (1-7) (Ang [1-7]).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32700055" target="_blank">32700055</a>
</td>
<td style="text-align:center;">
Additional facets include the sympathetic adrenergic system, for which adrenaline is the key effector; the hypothalamic-pituitary-adrenocortical axis; arginine vasopressin (synonymous with anti-diuretic hormone); the renin-angiotensin-aldosterone system, with angiotensin II and aldosterone the main effectors; and cholinergic anti-inflammatory and sympathetic inflammasomal pathways.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32708205" target="_blank">32708205</a>
</td>
<td style="text-align:center;">
The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. […] Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. […] Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. […] In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (p &lt; 0.01 and p = 0.03, respectively). […] In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. […] We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. […] Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32710674" target="_blank">32710674</a>
</td>
<td style="text-align:center;">
In conclusion, our data support that receiving renin-angiotensin-aldosterone system inhibitors does not predispose for suffering COVID-19 infection in ambulatory hypertensive people.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32711111" target="_blank">32711111</a>
</td>
<td style="text-align:center;">
Additionally, by inducing an imbalance in the renin-angiotensin-aldosterone system (RAAS) and the loss of ACE2 would favour the progression of inflammatory and thrombotic processes in the lungs.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32712300" target="_blank">32712300</a>
</td>
<td style="text-align:center;">
The use of ACEIs/ARBs (RAAS inhibitors) regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2 expression.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32718670" target="_blank">32718670</a>
</td>
<td style="text-align:center;">
Of interest, another mechanistic approach responds to considering the inhibition of the renin-angiotensin-aldosterone system (RAAS), which is exacerbated in COVID-19 infection because the virus binds to the enzyme ACE2, making more angiotensinII available to cause damage.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32721806" target="_blank">32721806</a>
</td>
<td style="text-align:center;">
Angiotensin-converting enzyme-2 (ACE2) receptor, regulation of the renin-angiotensin-aldosterone system (RAAS), and transmembrane serine protease 2 (TMPRSS2) action are critical for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry and infectivity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32726128" target="_blank">32726128</a>
</td>
<td style="text-align:center;">
The sex hormone estrogen interacts with the renin-angiotensin-aldosterone system, one of the most critical pathways in COVID-19 infectivity, and modulates the vasomotor homeostasis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32730512" target="_blank">32730512</a>
</td>
<td style="text-align:center;">
The renin-angiotensin-aldosterone system (RAAS) is the main plasma volume regulator, which maintains cardiovascular and hydrosaline homeostasis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32736906" target="_blank">32736906</a>
</td>
<td style="text-align:center;">
The rationale, concerns, and possible side effects of specific therapeutic measures, including anticoagulants, renin-angiotensin-aldosterone system inhibitors, and anti-inflammatory/antiviral medications applied to the treatment of COVID-19 are also discussed.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32738257" target="_blank">32738257</a>
</td>
<td style="text-align:center;">
A role for the renin-angiotensin-aldosterone-system in Severe Acute Respiratory Syndrome-Coronavirus-2 infection and in the development of COronaVIrus Disease-19 disease has generated remarkable concerns among physicians and patients. […] Even though a suggestive pathophysiological link between renin-angiotensin-aldosterone-system and the virus has been proposed, its pathogenic role remains very difficult to be defined. […] Although COronaVIrus Disease-19 targets preferentially older people with high prevalence of hypertension and extensive use of renin-angiotensin-aldosterone-system inhibitors, an independent role for hypertension and its therapies is not defined. […] We conclude that at this time, the overall available evidence fails to support a pathogenetic speaks against any harmful role for of renin-angiotensin-aldosterone-system inhibitors in COronaVIrus Disease-19. […] Consequently, we conclude that treatment with renin-angiotensin-aldosterone-system inhibitors should not be discontinued and, therefore, these therapies should not be interrupted.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32739908" target="_blank">32739908</a>
</td>
<td style="text-align:center;">
The mechanisms of vascular complications are complex and affect both the hemostatic system and immune responses, “inflammatory storm”, disorders of the renin-angiotensin-aldosterone system, endotheliopathy, etc.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32753148" target="_blank">32753148</a>
</td>
<td style="text-align:center;">
Upregulation of ACE2 mediates conversion of angiotensin II (vasoconstrictor) to angiotensin-(1-7) (vasodilator) and contributes to relatively low blood pressures, despite upregulation of other components of the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32777758" target="_blank">32777758</a>
</td>
<td style="text-align:center;">
Proposed aetiologies include hypovolemia, hemodynamic disturbance and inflammation but also specific factors like direct viral invasion, microvascular thrombosis, and altered regulation of the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786343" target="_blank">32786343</a>
</td>
<td style="text-align:center;">
Immune system and renin-angiotensin-aldosterone system dysregulation with associated cytokine release syndrome may be a key feature of early stage of SARS-CoV-2 organotropism and infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32788834" target="_blank">32788834</a>
</td>
<td style="text-align:center;">
The ongoing pandemic has stimulated study of the Renin Angiotensin Aldosterone System (RAAS), and how it can be manipulated to treat COVID-19. […] We detail the Physiology and Pharmacology of the RAAS including the effects of aldosterone and atrial natriuretic peptide.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32791497" target="_blank">32791497</a>
</td>
<td style="text-align:center;">
In this perspective, we will address the inherent immunological perturbations and alterations in the renin-angiotensin-aldosterone system in patients with obesity and COVID-19, and discuss how these impairments may underlie the increased susceptibility and more detrimental outcomes of COVID-19 in people with obesity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32791552" target="_blank">32791552</a>
</td>
<td style="text-align:center;">
As there is no evidence that inhibition of the renin-angiotensin-aldosterone-system is harmful in COVID-19, therapy should be continued as indicated in hypertension or heart failure patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32809116" target="_blank">32809116</a>
</td>
<td style="text-align:center;">
In this paper, we also review the pathogenesis of SARS-CoV-2 infection and how it worsens CVD and postulate that the differences in modulation of the renin-angiotensin-aldosterone system (RAAS) axis which controls angiotensin-converting enzyme (ACE)/ACE2 balance may be an important determinant of COVID-19 outcomes in Africa.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32815593" target="_blank">32815593</a>
</td>
<td style="text-align:center;">
In this article, the relationship between the Adrenergic system and the renin-angiotensin-aldosterone system (RAAS) is focused in COVID-19 and a vicious circle consisting of the Adrenergic system-RAAS-Angiotensin converting enzyme 2 (ACE2)-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (which is referred to as the “ARAS loop”) is proposed.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32818905" target="_blank">32818905</a>
</td>
<td style="text-align:center;">
ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32825954" target="_blank">32825954</a>
</td>
<td style="text-align:center;">
The interference on renin-angiotensin-aldosterone system (RAAS) activation, heme formation, and the immune response is responsible for infection diffusion, endothelial dysfunction, vasoconstriction, oxidative damage and releasing of inflammatory mediators.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32830286" target="_blank">32830286</a>
</td>
<td style="text-align:center;">
The role of renin-angiotensin-aldosterone system (RAAS) inhibitors, notably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), in the COVID-19 pandemic has not been fully evaluated.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32834792" target="_blank">32834792</a>
</td>
<td style="text-align:center;">
•There is a concern that renin-angiotensin-aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32835316" target="_blank">32835316</a>
</td>
<td style="text-align:center;">
In patients with serial ECGs, there was no significant change in the QTc interval in prespecified subgroups of interest, including those with prevalent cardiovascular disease or baseline use of renin-angiotensin-aldosterone axis inhibitors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32848769" target="_blank">32848769</a>
</td>
<td style="text-align:center;">
The renin-angiotensin-aldosterone system (RAAS) component ACE2 and DPP4 are proteins dysregulated in diabetes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32852721" target="_blank">32852721</a>
</td>
<td style="text-align:center;">
There are several controversial hypotheses on the potentially harmful or beneficial effects of antihypertensive drugs acting on the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32853823" target="_blank">32853823</a>
</td>
<td style="text-align:center;">
The problem here is that in addition to be a receptor for the SARS-CoV-2 entry into the host cells, ACE2 acts as a key component of the renin-angiotensin-aldosterone system (RAAS) aimed at the generation of a cascade of vasoactive peptides coordinating several physiological processes. […] Since intrinsic disorder might play a role in the functionality of query proteins and be related to the COVID-19 pathogenesis, this work represents an important disorder-based outlook of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32864784" target="_blank">32864784</a>
</td>
<td style="text-align:center;">
Therefore, the use of renin-angiotensin-aldosterone system inhibitors (RASis) in COVID-19 patients could be hypothetically considered, though sufficient evidence is not presented by the scientific community.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32872736" target="_blank">32872736</a>
</td>
<td style="text-align:center;">
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there have been concerns about the association between exposure to renin-angiotensin-aldosterone system (RAAS) inhibitors and the risk and severity of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32875490" target="_blank">32875490</a>
</td>
<td style="text-align:center;">
While the potential for benefit with the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and the risks from stopping them is more evident, potential harm by RAΑSi may also be caused by the increase in the activity of the ACE2 receptor, the inefficient counter regulatory axis in the lungs in which the proinflammatory prolyloligopeptidase (POP) is the main enzyme responsible for the conversion of deleterious angiotensin (ANG) II to protective ANG [1-7] and the proinflammatory properties of ACE2(+) cells infected with SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32877500" target="_blank">32877500</a>
</td>
<td style="text-align:center;">
This position statement of the Department of Hypertension of the Brazilian Society of Nephrology (SBN) addresses the controversy surrounding the use or suspension/replacement of the renin-angiotensin-aldosterone system blockers (particularly inhibitors of the angiotensin-converting enzyme or angiotensin II AT1 receptor blockers) prophylactically in individuals using these drugs, due to the possibility of allegedly worsening the prognosis of hypertensive patients infected with SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32899833" target="_blank">32899833</a>
</td>
<td style="text-align:center;">
In this line, activation of the non-canonical pathway of the renin-angiotensin-aldosterone system (RAAS) could improve CV homeostasis under COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32901615" target="_blank">32901615</a>
</td>
<td style="text-align:center;">
Marked inflammatory process found in severe forms of COVID-19, the complement activation, the cytokine storm, and disruption of the renin-angiotensin-aldosterone system are involved in the onset of thrombotic microangiopathy and large vessel coagulopathy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32908071" target="_blank">32908071</a>
</td>
<td style="text-align:center;">
The impaired regulation of renin-angiotensin-aldosterone system (RAAS) has been seen in COVID-19 patients, but whether RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are responsible for worsening of clinical conditions remains unknown.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32917504" target="_blank">32917504</a>
</td>
<td style="text-align:center;">
We hypothesized that the renal abundance of angiotensin-converting enzyme (ACE) 2, the cell surface receptor for SARS-CoV-2, may be modulated by diabetes and agents that block the renin-angiotensin-aldosterone system (RAAS).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32922297" target="_blank">32922297</a>
</td>
<td style="text-align:center;">
ACE2 serves as an endogenous inhibitor of inflammatory signals associated with four major regulator systems: the renin-angiotensin-aldosterone system (RAAS), the complement system, the coagulation cascade, and the kallikrein-kinin system (KKS).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926815" target="_blank">32926815</a>
</td>
<td style="text-align:center;">
Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32928868" target="_blank">32928868</a>
</td>
<td style="text-align:center;">
More studies reported upregulation than downregulation with ACE-I (n=22), ARBs (n=55), insulin (n=8), thiazolidinedione (n=7) aldosterone agonists (n=3), statins (n=5), oestrogens (n=5) calcium channel blockers (n=3) glucagon-like peptide 1 (GLP-1) agonists (n=2) and Non-steroidal anti-inflammatory drugs (NSAIDs) (n=2).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32933039" target="_blank">32933039</a>
</td>
<td style="text-align:center;">
In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. […] Group A (n = 39) were given vasodilator agents or renin-angiotensin-aldosterone system (RAAS) inhibitors and group B (n = 30) were given canrenone i.v.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32935928" target="_blank">32935928</a>
</td>
<td style="text-align:center;">
SARS-CoV-2 can cause CVD by inducing cytokine storms, creating an imbalance in the oxygen supply and demand and disrupting the renin-angiotensin-aldosterone system; SARS-CoV-2 infection can also lead to the development of CVD through the side effects of therapeutic drugs, psychological factors, and aggravation of underlying CVD.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32943474" target="_blank">32943474</a>
</td>
<td style="text-align:center;">
Controversies of renin-angiotensin-aldosterone system inhibitors usage in patients with COVID-19 and meticulous handling of case with acute coronary syndrome categorically stresses cardiologists to bust the myths hovering around and set a standard guideline to counterfeit the fatality with timely diagnosis and treatment of COVID-19-induced ACI.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32949380" target="_blank">32949380</a>
</td>
<td style="text-align:center;">
Concerns have been raised about the possible harmfulness of angiotensin-converter enzyme inhibitors (ACEi) and aldosterone receptor blockers (ARB) in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32966970" target="_blank">32966970</a>
</td>
<td style="text-align:center;">
ACE2 is an established component of the ‘protective arm’ of the renin-angiotensin-aldosterone-system (RAAS) that opposes ACE/angiotensin II (ANG II) pressor and tissue remodelling actions.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32967329" target="_blank">32967329</a>
</td>
<td style="text-align:center;">
Furthermore, vitamin D reduces renin-angiotensin-aldosterone system activation and, consequently, decreases ROS generation and improves the prognosis of SARS-CoV-2 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32968307" target="_blank">32968307</a>
</td>
<td style="text-align:center;">
All patients received loop diuretics, 97.2% beta-blockers, 64.9% an aldosterone antagonist, 60.9% sacubitril/valsartan (S/V), and 72.2% of the remaining patients were on angiotensin-converting enzyme inhibitor or valsartan therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32969367" target="_blank">32969367</a>
</td>
<td style="text-align:center;">
BACKGROUND Use of renin-angiotensin-aldosterone system inhibitors in coronavirus disease 2019 (COVID-19) patients lacks evidence and is still controversial.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32981365" target="_blank">32981365</a>
</td>
<td style="text-align:center;">
ACE2 (angiotensin-converting enzyme 2) is a key component of the renin-angiotensin-aldosterone system.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32984543" target="_blank">32984543</a>
</td>
<td style="text-align:center;">
There is clear evidence that, by targeting the angiotensin-converting enzyme II (ACE2) -its natural receptor-, SARS-CoV-2 would mainly affect the renin-angiotensin-aldosterone system (RAAS), whose imbalance triggers diverse symptomatology-associated pathological processes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32992048" target="_blank">32992048</a>
</td>
<td style="text-align:center;">
The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID-19 severity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32993622" target="_blank">32993622</a>
</td>
<td style="text-align:center;">
Abnormalities in the renin-angiotensin-aldosterone system (RAAS), angiotensin-converting enzyme-2 (ACE2) and the androgen-driven transmembrane serine protease 2 (TMPRSS2) have been elicited as key modulators of SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32995920" target="_blank">32995920</a>
</td>
<td style="text-align:center;">
The last decade was crucial for our understanding of the renin-angiotensin-aldosterone system (RAAS) as a two-axis, counter-regulatory system, divided into the classical axis, formed by angiotensin-converting enzyme (ACE), angiotensin II (Ang II), and the angiotensin type 1 receptor (AT1R), and the alternative axis comprising angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) (Ang-(1-7)), and the Mas receptor.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32998337" target="_blank">32998337</a>
</td>
<td style="text-align:center;">
Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33006442" target="_blank">33006442</a>
</td>
<td style="text-align:center;">
After adjustment, subjects with pre-admission usage of renin-angiotensin-aldosterone system (RAAS) inhibitors (HR = 0.35, 95%CI 0.14-0.86, P = .022) had a lower risk of adverse clinical outcomes, including death, acute respiratory distress syndrome, respiratory failure, septic shock, mechanical ventilation, and intensive care unit admission.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33021511" target="_blank">33021511</a>
</td>
<td style="text-align:center;">
The role of renin-angiotensin-aldosterone system (RAAS) blockers during the coronavirus disease 2019 (COVID-19) pandemic is a matter of controversies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33023356" target="_blank">33023356</a>
</td>
<td style="text-align:center;">
Our findings suggest the protective role of renin-angiotensin-aldosterone system inhibition in patients with high cardiovascular risk affected by COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33025652" target="_blank">33025652</a>
</td>
<td style="text-align:center;">
CCBs showed a similar pattern for immune function (lymphocyte percentage 0.21, 95% CI 0.05 to 0.36; neutrophil percentage -0.23, 95% CI -0.39 to -0.08) but had no effect on TNF-α, as did potassium-sparing diuretics and aldosterone antagonists, and vasodilator antihypertensives.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33031192" target="_blank">33031192</a>
</td>
<td style="text-align:center;">
Given the relationship of SARS-CoV-2 with the renin angiotensin aldosterone system, further evaluation of angiotensin II for the treatment of COVID-19 related shock is warranted.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33038424" target="_blank">33038424</a>
</td>
<td style="text-align:center;">
ACE2 expression levels were unaltered by exposures to renin angiotensin aldosterone system inhibitors in diabetic kidney disease.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33039544" target="_blank">33039544</a>
</td>
<td style="text-align:center;">
Incidentally, the renin-angiotensin-aldosterone system (RAAS) is integral to physiologic control of both ACE and ACE2 expression, and is an essential system utilized by SARS-CoV-2, albeit with varying schools of thought on how it can affect viral entry.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33043967" target="_blank">33043967</a>
</td>
<td style="text-align:center;">
The role of the renin-angiotensin-aldosterone system in COVID-19 is controversially discussed. […] SARS-CoV-2 enters host cells by binding to angiotensin-converting enzyme 2 and activity of the renin-angiotensin-aldosterone system may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19. […] In this prospective single-center study, we determined the serum levels of ACE-2, angiotensin II and aldosterone in patients with COVID-19 compared to control patients presenting with similar symptoms in the emergency unit. […] Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. […] In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33064080" target="_blank">33064080</a>
</td>
<td style="text-align:center;">
Despite the rapid ongoing evolution of information about this pandemic, this review aims to highlight cardiovascular pathologies related to COVID-19 as either comorbidities, including concerns and uncertainty regarding the effect of renin-angiotensin-aldosterone system (RAAS) inhibitors on angiotensin conversion enzyme 2, or cardiovascular complications.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33071957" target="_blank">33071957</a>
</td>
<td style="text-align:center;">
Unexpected hyperkalemia in CS patients under treatment with heparin might be the signal of aldosterone suppression.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33082849" target="_blank">33082849</a>
</td>
<td style="text-align:center;">
Angiotensin converting enzyme-2 (ACE-2) mediated cellular entry of SARS-Cov2 leads to receptor shedding of ACE-2 and disrupts the renin angiotensin aldosterone axis (RAAS).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084001" target="_blank">33084001</a>
</td>
<td style="text-align:center;">
This paper presents a brief overview of the complex interaction between age, hypertension, the renin-angiotensin-aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33093403" target="_blank">33093403</a>
</td>
<td style="text-align:center;">
KTRs with AKI had more preexisting renin angiotensin aldosterone system inhibitor use than KTRs without AKI (P = 0.03).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33093945" target="_blank">33093945</a>
</td>
<td style="text-align:center;">
We provide further support to the theory of renin-angiotensin-aldosterone (RAS) activation, discuss the strengths and weaknesses of implicating RAS involvement and highlight the importance of calculating the transtubular potassium gradient to identify those at risk of hypokalaemia and its complications.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33098835" target="_blank">33098835</a>
</td>
<td style="text-align:center;">
Bioactive peptides with unique amino acid sequences can mitigate such targets including, type II transmembrane serine proteases (TMPRSS2) inhibition, furin cleavage, and renin-angiotensin-aldosterone system (RAAS) members.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33121978" target="_blank">33121978</a>
</td>
<td style="text-align:center;">
Antithrombotics (32.5%; n = 37) were most commonly evaluated, followed by pulmonary vasodilators (14.0%; n = 16), renin-angiotensin-aldosterone system-related therapies (12.3%; n = 14), and colchicine (8.8%; n = 10).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33123087" target="_blank">33123087</a>
</td>
<td style="text-align:center;">
We suggest that increased inflammation, activation of renin-angiotensin-aldosterone system, elevated adipokines and higher ectopic fat may be the factors contributing to the disease severity, in particular deteriorating the cardiovascular and lung function, in obese individuals.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33124029" target="_blank">33124029</a>
</td>
<td style="text-align:center;">
We further shed light on the role of the renin-angiotensin aldosterone system and its inhibitors in the context of COVID-19 and discuss the potential impact of antiviral and anti-inflammatory treatment options.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33129663" target="_blank">33129663</a>
</td>
<td style="text-align:center;">
Outcomes among patients with HF were similar, regardless of LVEF or renin-angiotensin-aldosterone inhibitor use.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33138935" target="_blank">33138935</a>
</td>
<td style="text-align:center;">
The role of treatment with renin-angiotensin-aldosterone system blockers at the onset of COVID-19 infection is not known in the geriatric population.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33146371" target="_blank">33146371</a>
</td>
<td style="text-align:center;">
Angiotensin converting enzyme (ACE) is well-known for its role in blood pressure regulation via the renin-angiotensin aldosterone system (RAAS) but also functions in fertility, immunity, haematopoiesis and diseases such as obesity, fibrosis and Alzheimer’s dementia.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33153216" target="_blank">33153216</a>
</td>
<td style="text-align:center;">
Both entry from the luminal and basolateral sides of the renal tubular cells are the possible routes for COVID-19, and the microthrombi associated with severe sepsis and the dysregulated renin-angiotensin-aldosterone system worsen further renal injury in SARS-CoV-2-associated AKI.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33154144" target="_blank">33154144</a>
</td>
<td style="text-align:center;">
The association between the use of renin-angiotensin-aldosterone (RAAS) inhibitors and the risk of mortality from COVID-19 is unclear.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33171852" target="_blank">33171852</a>
</td>
<td style="text-align:center;">
The virus SARS-CoV-2 employs the Angiotensin-converting enzyme 2 (ACE2), a component of the RAAS (Renin-Angiotensin-Aldosterone System) system, as a receptor for entry into the cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33172748" target="_blank">33172748</a>
</td>
<td style="text-align:center;">
COVID-19 can cause cardiovascular complications or deterioration of coexisting CVD through direct or indirect mechanisms, including viral toxicity, dysregulation of the renin-angiotensin-aldosterone system (RAAS), endothelial cell damage and thromboinflammation, cytokine storm, and oxygen supply-demand mismatch.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33181156" target="_blank">33181156</a>
</td>
<td style="text-align:center;">
Receiving immunosuppression or renin-angiotensin-aldosterone system inhibitors at presentation did not increase the risk of death or acute kidney injury in the glomerulonephritis cohort.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33186672" target="_blank">33186672</a>
</td>
<td style="text-align:center;">
In the present review, we summarize examples underlying fallacious reasoning recommendations regarding treatment with Renin-Angiotensin-Aldosterone inhibitors (RAASi) in the COVID-19 context.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33188364" target="_blank">33188364</a>
</td>
<td style="text-align:center;">
Angiotensin-converting enzyme 2 (ACE2), which is part of the renin-angiotensin-aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33196058" target="_blank">33196058</a>
</td>
<td style="text-align:center;">
ACE2 is integral to the renin-angiotensin-aldosterone system (RAAS), and SARS-CoV-2 down-regulates protein expression levels of ACE2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33202960" target="_blank">33202960</a>
</td>
<td style="text-align:center;">
These observations implicate an active role of metabolic syndrome, systemic and tissue islet renin-angiotensin-aldosterone system, redox stress, inflammation, islet fibrosis, amyloid deposition along with β-cell dysfunction and apoptosis in those who develop T2DM.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33211434" target="_blank">33211434</a>
</td>
<td style="text-align:center;">
The breakthrough of the secrets of hypertension and the renin-angiotensin-aldosterone system (RAAS) is one of the legends of medicine. […] The puzzle of this elegant cascade is completed by aldosterone isolation by the collaboration of Tait spouses and Tadeus Rechstein.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33217033" target="_blank">33217033</a>
</td>
<td style="text-align:center;">
Animal studies suggest that renin-angiotensin-aldosterone system (RAAS) blockers might increase the expression of ACE2 and potentially increase the risk of SARS-CoV-2 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33222412" target="_blank">33222412</a>
</td>
<td style="text-align:center;">
Renin-angiotensin-aldosterone system inhibitors (RAASi) improve outcomes in cardiorenal disease but concerns have been raised over increased risk of incident hospitalization and death from coronavirus disease 2019 (COVID-19).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33233531" target="_blank">33233531</a>
</td>
<td style="text-align:center;">
In line with these genetic profiling studies, the broad spectrum of COVID-19 illness could be explained by immuno-pathological regulation of these critical immunogenetic pathways through various epigenetic mechanisms, which further interconnect to other vital components such as those in the renin-angiotensin-aldosterone system (RAAS) because of its direct interaction with the virus causing COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33249290" target="_blank">33249290</a>
</td>
<td style="text-align:center;">
Bronchoalveolar lavage fluid from coronavirus disease-2019 (COVID-19) subjects showed a critical imbalance in the renin-angiotensin-aldosterone system with the upregulated expression of ACE2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33252294" target="_blank">33252294</a>
</td>
<td style="text-align:center;">
Estradiol protects the vascular system, mediating with the renin-angiotensin-aldosterone system, whereas testosterone enhances the levels of angiotensin-converting enzyme and the transmembrane protease serine-type 2, thus delaying viral clearance in men as compared to women.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33254506" target="_blank">33254506</a>
</td>
<td style="text-align:center;">
The angiotensin converting enzyme-2 (ACE-2), a component in the renin-angiotensin-aldosterone system (RAAS), plays as cell surface receptors for SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33254538" target="_blank">33254538</a>
</td>
<td style="text-align:center;">
We hypothesize that overreaction of the renin-angiotensin-aldosterone may account for the myriad of unusual biochemical and clinical abnormalities noted in patients infected with SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33275540" target="_blank">33275540</a>
</td>
<td style="text-align:center;">
ACE2 is crucial for maintaining tissue homeostasis and negatively regulates the renin-angiotensin-aldosterone system (RAAS) in humans.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33278189" target="_blank">33278189</a>
</td>
<td style="text-align:center;">
They are inhibited by protease nexin 1 or serine E2 (PN1) that is upregulated by angiotensin II but downregulated by aldosterone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33283618" target="_blank">33283618</a>
</td>
<td style="text-align:center;">
Plasma vitamin D levels and evolutionary adaptations of the renin-angiotensin-aldosterone system (RAAS) in Black people differ considerably from those of other races.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33303654" target="_blank">33303654</a>
</td>
<td style="text-align:center;">
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or not renin-angiotensin-aldosterone system inhibitors (RAASi) would be beneficial to COVID-19 cases remains controversial.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33304284" target="_blank">33304284</a>
</td>
<td style="text-align:center;">
By describing ACE2 and the whole Renin Angiotensin Aldosterone System (RAAS) we may better understand whether specific cell types may be affected by SARS-CoV-2 and whether their functioning can be disrupted in case of an infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33312744" target="_blank">33312744</a>
</td>
<td style="text-align:center;">
This activates the renin angiotensin aldosterone mechanism (RAAM).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33321496" target="_blank">33321496</a>
</td>
<td style="text-align:center;">
AKI in COVID-19 has a multifactorial origin, in which direct viral invasion of kidney cells, activation of the renin-angiotensin aldosterone system, a hyperinflammatory response, hypercoagulability, and nonspecific factors such as hypotension and hypoxemia may be involved.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33327700" target="_blank">33327700</a>
</td>
<td style="text-align:center;">
Nonetheless, unique features of this pathogen, e.g. direct insult leading to myocarditis and renin-angiotensin-aldosterone axis dysregulation, must be taken into account.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33329934" target="_blank">33329934</a>
</td>
<td style="text-align:center;">
Direct viral toxicity, pro-inflammatory and pro-thrombotic induction, endothelial damage, immune imbalance, and dysregulation of the renin-angiotensin-aldosterone system are the mechanisms underlying the viral potential of multiple organ damage.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33342421" target="_blank">33342421</a>
</td>
<td style="text-align:center;">
It should also be considered that all components of the reninangiotensin-aldosterone system (RAAS) are located in the lung tissues.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33364877" target="_blank">33364877</a>
</td>
<td style="text-align:center;">
The effects of chronic renin-angiotensin-aldosterone system (RAAS) blockers usage on adverse outcomes and disease severity remain uncertain in COVID-19 patients with hypertension.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33375676" target="_blank">33375676</a>
</td>
<td style="text-align:center;">
Our data show a high prevalence of hypertension, more likely treated with renin-angiotensin-aldosterone system (RASS) inhibitors, among COVID-19 patients not requiring hospitalization.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33378401" target="_blank">33378401</a>
</td>
<td style="text-align:center;">
Retrospective studies on the use of Renin-Angiotensin-Aldosterone System blockade in patients with Coronavirus Disease 2019 (COVID-19) have been informative but conflicting, and prospective studies are required to demonstrate the safety, tolerability, and outcomes of initiating these agents in hospitalized patients with COVID-19 and hypertension.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33382450" target="_blank">33382450</a>
</td>
<td style="text-align:center;">
We will review evidence for the role of the renin-angiotensin-aldosterone system (RAAS), the risk of pre-existing cardiovascular disease in COVID-19 susceptibility and course, and the mechanism of acute and long-term myocardial injury.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33387941" target="_blank">33387941</a>
</td>
<td style="text-align:center;">
Angiotensin-converting enzyme 2 (ACE2), an important component of the renin-angiotensin-aldosterone system (RAAS), displays circadian rhythmicity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33389262" target="_blank">33389262</a>
</td>
<td style="text-align:center;">
ACE2 is a key regulator of the renin-angiotensin-aldosterone system (RAAS).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33398362" target="_blank">33398362</a>
</td>
<td style="text-align:center;">
To date, multiple theories relating to the pure effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on COVID-19 infections have been postulated.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33404127" target="_blank">33404127</a>
</td>
<td style="text-align:center;">
The role of antihypertensives, especially Renin-Angiotensin-Aldosterone System inhibitors, is still debatable in COVID-19-related severity and outcome.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33404363" target="_blank">33404363</a>
</td>
<td style="text-align:center;">
In particular, we now better understand the complexity of the renin-angiotensin-aldosterone system (RAAS) and the important role of angiotensin converting enzyme (ACE)-2 in viral binding.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33414726" target="_blank">33414726</a>
</td>
<td style="text-align:center;">
Literature on COVID-19 highlighted the central role of the Renin Angiotensin Aldosterone System in the determinism of SARS-CoV2 cellular internalization in the target tissues.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33422689" target="_blank">33422689</a>
</td>
<td style="text-align:center;">
Angiotensin-converting enzyme 2 (ACE2) is an important player of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II into angiotensin (1-7).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33423528" target="_blank">33423528</a>
</td>
<td style="text-align:center;">
After initially hypothesizing a positive relationship between use of renin-angiotensin-aldosterone system inhibitors and risk of coronavirus disease 2019 (COVID-19), more recent evidence suggests negative associations.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33432484" target="_blank">33432484</a>
</td>
<td style="text-align:center;">
Furthermore, they repair the renin-angiotensin-aldosterone system (RAAS) malfunction, increase alveolar fluid clearance, and reduce the chance of hypercoagulation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33435650" target="_blank">33435650</a>
</td>
<td style="text-align:center;">
Herein we discuss the complex interaction between the Renin-Angiotensin-Aldosterone System (RAAS), its receptors, and the interaction with the Kallikrein-Kinin-System (KKS) and the potential activation of the coagulation cascade.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33437743" target="_blank">33437743</a>
</td>
<td style="text-align:center;">
Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33438198" target="_blank">33438198</a>
</td>
<td style="text-align:center;">
Stroke, asthma, chronic obstructive pulmonary disease and treatment with renin-angiotensin-aldosterone inhibitors (RAASi) were independent risk factors of ICU mortality in the pre-specified primary analyses; treatment with statins was protective.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33443121" target="_blank">33443121</a>
</td>
<td style="text-align:center;">
ACE2 is part of the counter-regulatory renin-angiotensin-aldosterone system and is also expressed in the lower respiratory tract along the alveolar epithelium.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33447763" target="_blank">33447763</a>
</td>
<td style="text-align:center;">
Emerging epidemiological studies suggested that Renin-Angiotensin-Aldosterone system (RAAS) inhibitors may increase infectivity and severity of COVID-19 by modulating the expression of ACE2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33448738" target="_blank">33448738</a>
</td>
<td style="text-align:center;">
Ongoing research investigates potential of anti-viral and anti-inflammatory agents along with safety and efficacy of commonly prescribed drugs such as renin-angiotensin-aldosterone system blockers.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33458761" target="_blank">33458761</a>
</td>
<td style="text-align:center;">
ACE2 usually converts Angiotensin I in the renin-angiotensin-aldosterone system to Angiotensin II, which affects blood pressure levels.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33462706" target="_blank">33462706</a>
</td>
<td style="text-align:center;">
CVD diagnoses, use of renin-angiotensin-aldosterone system (RAAS) antagonists: ACEi, ARBs, and aldosterone antagonists, were ascertained.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33463113" target="_blank">33463113</a>
</td>
<td style="text-align:center;">
We then present a comprehensive view on host cells and the significance of gene variants affecting activation enzymes, supportive entry, and spread mechanisms in humans including renin-angiotensin-aldosterone system (RAAS) a pathway results in certain phenotypes or exacerbate infection-related phenotypes in different organs, hence causes variable clinical manifestations.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33477294" target="_blank">33477294</a>
</td>
<td style="text-align:center;">
It has been proposed that spironolactone may prevent acute lung injury in COVID-19 infection due to its pleiotropic effects with favorable renin-angiotensin-aldosterone system (RAAS) and ACE2 expression, reduction in transmembrane serine protease 2 (TMPRSS2) activity and antiandrogenic action, and therefore it may prove to act as additional protection for patients at highest risk of severe pneumonia.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33507655" target="_blank">33507655</a>
</td>
<td style="text-align:center;">
Finally, renin-angiotensin-aldosterone inhibitors do not appear to increase the risk of an infection by COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33519802" target="_blank">33519802</a>
</td>
<td style="text-align:center;">
This viewpoint presents: (1) a brief introduction regarding the renin-angiotensin-aldosterone system (RAAS), detailing its receptors, molecular synthesis, and degradation routes; (2) a description of the proposed early changes in the RAAS in response to SARS-CoV-2 infection, including biological scenarios for the best and worst prognoses; and (3) the physiological pathways and reasoning for changes in the RAAS following SARS-CoV-2 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33520683" target="_blank">33520683</a>
</td>
<td style="text-align:center;">
This present review aims to comprehensively summarize the up-to-date scientific literatures on biological activities of plant- and mushroom-derived compounds relevant to mechanistic targets involved in SARS-CoV-2 infection and inflammatory-associated pathogenesis, including viral entry, replication and release, and the renin-angiotensin-aldosterone system (RAAS). studies were excluded. molecular docking analysis, herein, we provide a total of 150 natural compounds as potential candidates for development of new anti-COVID-19 drugs with higher efficacy and lower toxicity than the existing therapeutic agents.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33525440" target="_blank">33525440</a>
</td>
<td style="text-align:center;">
During transmission, the renin-aldosterone-angiotensin-system (RAAS) is involved with the spike protein of SARS-CoV-2, attaching to its natural receptor angiotensin-converting enzyme 2 (ACE 2) in host cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33537555" target="_blank">33537555</a>
</td>
<td style="text-align:center;">
The renin-angiotensin-aldosterone system (RAAS) is strictly involved in COVID-19 because angiotensin converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 and also converts pro-inflammatory angiotensin (Ang) II into anti-inflammatory Ang(1-7).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33539316" target="_blank">33539316</a>
</td>
<td style="text-align:center;">
Objective While evidence on the interface between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and the renin-angiotensin-aldosterone-system (RAAS) is accumulating, clinical data on RAAS peptide alteration among coronavirus disease-19 (COVID-19) patients is missing.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33542445" target="_blank">33542445</a>
</td>
<td style="text-align:center;">
These drugs include chloroquine (CQ), hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir (LPV/r), atazanavir (ATV), favipiravir (FVP), nevirapine (NVP), efavirenz (EFV), oseltamivir, remdesivir, anakinra, tocilizumab (TCZ), eculizumab, heme oxygenase 1 (HO-1) regulators, renin-angiotensin-aldosterone system (RAAS) inhibitors, ivermectin, and nitazoxanide.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33544293" target="_blank">33544293</a>
</td>
<td style="text-align:center;">
Aiming to show clinical outcome of renin-angiotensin-aldosterone system blockers in hospital treatment of hypertensive patients with coronavirus disease 2019, systematically searched literatures through five databases were intensively appraised using The Grading of Recommendations Assessment, Development and Evaluation checklists for cohort studies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33546734" target="_blank">33546734</a>
</td>
<td style="text-align:center;">
The aim of the RAAS-COVID-19 randomized control trial is to evaluate whether an upfront strategy of temporary discontinuation of renin angiotensin aldosterone system (RAAS) inhibition versus continuation of RAAS inhibition among patients admitted with established COVID-19 infection has an impact on short term clinical and biomarker outcomes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33563197" target="_blank">33563197</a>
</td>
<td style="text-align:center;">
Even though ACE-2 is significant in the renin-angiotensin-aldosterone system (RAAS) regulation that exhibits protection to various organs, they play a significant role in COVID-19 disease pathogenesis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33564823" target="_blank">33564823</a>
</td>
<td style="text-align:center;">
A growing number of observational studies evaluating the effects of certain drugs have been conducted, including several assessing whether hydroxychloroquine improves outcomes in infected individuals and whether renin-angiotensin-aldosterone system inhibitors have detrimental effects.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33584343" target="_blank">33584343</a>
</td>
<td style="text-align:center;">
ACE2 has extensive biological activities as a component of the renin-angiotensin-aldosterone system (RAAS) and plays a pivotal role as counter-regulator of angiotensin II (Ang II) activity by converting the latter to Ang (1-7).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33584499" target="_blank">33584499</a>
</td>
<td style="text-align:center;">
Although traditionally a rare condition, PRES is likely to be more common among patients with COVID-19 pathobiology there is Renin downregulation of ACE2 receptors, involvement of Renin-Angiotensin-Aldosterone system, endotheliitis, cytokine storm, and hyper-immune response.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33587202" target="_blank">33587202</a>
</td>
<td style="text-align:center;">
Our results suggest that previously reported associations of COVID-19 mortality with body mass index, low vitamin D, air pollutants, renin-angiotensin-aldosterone system inhibitors may be explained by the aforementioned factors.
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/platcovid/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/platcovid/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/platcovid/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
